Search results for "EVENTS"

showing 10 items of 514 documents

"Table 1" of "Search for pairs of highly collimated photon-jets in $pp$ collisions at $\sqrt{s}$ = 13 TeV with the ATLAS detector"

2018

Distribution of the reconstructed diphoton mass for data events passing the analysis selection, in the low-$\Delta E$ category. There are no data events above 2700 GeV.

Number of eventsInvariant mass13000Photon-jet
researchProduct

"Table 2" of "Search for pairs of highly collimated photon-jets in $pp$ collisions at $\sqrt{s}$ = 13 TeV with the ATLAS detector"

2018

Distribution of the reconstructed diphoton mass for data events passing the analysis selection, in the high-$\Delta E$ category. There are no data events above 2700 GeV.

Number of eventsInvariant mass13000Photon-jet
researchProduct

Is context a crucial factor in distinguishing between intrusions and obsessions in patients with obsessive‐compulsive disorder?

2021

Objective Some cognitive models of obsessive‐compulsive disorder (OCD) posit that intrusions exist on a continuum with obsessions; others consider that they may be unrelated phenomena that differ in the context where they occur. We aimed to examine and compare, at two different moments, the context of the occurrence of intrusions and obsessions. Method Sixty‐eight patients with OCD completed an interview appraising their most upsetting obsession and intrusion. Results At their onset, the obsessions/intrusions were associated with experiencing negative emotional states and life events, and they were more likely to appear in 'inappropriate' contexts. The context of the obsessions/intrusions d…

Obsessive-Compulsive Disorder050103 clinical psychologyPersonality InventoryEmotions05 social sciencesLife eventsContext (language use)Cognition030227 psychiatryDevelopmental psychology03 medical and health sciencesClinical PsychologyIntrusion0302 clinical medicineArts and Humanities (miscellaneous)Obsessive compulsiveHumans0501 psychology and cognitive sciencesIn patientObsessive BehaviorPsychologyJournal of Clinical Psychology
researchProduct

Record of latest Barremian-Cenomanian environmental change in tectonically controlled depressions from the Jura-Burgundy threshold (Jura Mountains, e…

2019

The area of the western Jura Mountains constitutes the former Jura-Burgundy threshold between the Tethys Ocean and the epicontinental Paris Basin Sea. During the Barremian, the area was covered by a shallow-water Urgonian carbonate platform. Tectonic processes influenced the architecture of the Urgonian platform and were notably responsible for the formation of fault-related depressions on top of the Urgonian series, which were subsequently transformed into incised valleys and then to marine depocenters. Their sedimentary infills are mostly represented by the Perte-du-Rhône Formation and record stepwise environmental change on the innermost platform, which was strongly influenced by the nea…

Oceanic anoxic eventsUrgonian platformNW-Tethyan margin[SDU.STU.ST] Sciences of the Universe [physics]/Earth Sciences/StratigraphySyntectonic sedimentationGlobal changesCretaceous
researchProduct

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

2018

Background: The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. Methods: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded Access Program. Objective response rate, progression-free survival and overall survival were evaluated. Patients were monitored for adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events. Results: Among 530 patients evaluated for KRAS mutations, 206 (39%) were positive while 324 (61%) were KRAS wild-type mutations. KRAS status did not influence nivolumab efficacy in terms of …

OncologyAdultMalemedicine.medical_specialtyCancer Researchmedicine.disease_causePredictive markersArticleProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinoma80 and overHumansProgression-free survivalLung cancerNon-Small-Cell LungneoplasmsAgedAged 80 and overbusiness.industryCarcinomaCancerCommon Terminology Criteria for Adverse EventsMiddle Agedmedicine.diseasedigestive system diseasesProgression-Free Survivalrespiratory tract diseasesNivolumabOncologyAdult; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Female; Humans; Male; Middle Aged; Mutation; Nivolumab; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); ImmunotherapyOncology; Cancer Research030220 oncology & carcinogenesisExpanded accessMutationFemaleKRASImmunotherapyNivolumabbusinessNon-small-cell lung cancer
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct

Comparative Analyses of Two Established Scores to Assess the Stability of Spinal Bone Metastases Before and After Palliative Radiotherapy

2021

Background and PurposeTo compare two validated spinal instability scores regarding the stabilizing effects and skeletal-related events (SREs) of palliative radiotherapy (RT) in patients with spinal bone metastases (SBM).Materials and MethodsTwo hundred eighty-two osteolytic SBM of lung or breast cancer patients were analyzed for stability before and following RT based on the Spinal Instability Neoplastic Score (SINS) or the Taneichi score. Score concordance was quantified by absolute agreement and Cohen’s kappa coefficient. SREs were defined as fractures or local progression after RT. OS was quantified as the time between the start of RT and death from any cause.ResultsAt 3 and 6 months aft…

OncologyCancer Researchmedicine.medical_specialtyFuture studiesConcordancemedicine.medical_treatmentCohen's kappaBreast cancerPalliative radiotherapyInternal medicinemedicineSINSRC254-282radiotherapyOriginal Researchbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensSpinal instabilityspinal bone metastasesmedicine.diseaseskeletal-related eventsRadiation therapyinstabilityOncologybusinessKappaFrontiers in Oncology
researchProduct

70 Patient reported outcome in platinum-resistant recurrent ovarian cancer and metastatic breast cancer treated with metronomic chemotherapy

2021

Introduction/Background* In the treatment of both platinum-resistant recurrent ovarian cancer (ROC) and metastatic breast cancer (MBC), symptom control and maintenance of quality of life (QoL) play a crucial role. In the advanced stage of disease, metronomic chemotherapy (MCT) may be a favourable treatment option. The aim of this study is to assess the QoL of heavily pretreated patients with ROC and MBC treated with MCT. Methodology PROmetronomic, FoR.UM 19-02193, is a monocentric, open-label, single-arm observational study to assess health-related patient-reported outcome data in ROC and MBC patients treated with MCT (cyclophosphamide 50 mg p.o. daily ± methotrexate 2.5 mg p.o. every other…

OncologyChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerCommon Terminology Criteria for Adverse Eventsmedicine.diseaseMetronomic ChemotherapyMetastatic breast cancerTolerabilityQuality of lifeInternal medicinemedicinePatient-reported outcomebusinessOvarian cancer
researchProduct

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

2018

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysi…

OncologyHepatocellular carcinomalaw.inventionLeukocyte Count0302 clinical medicineRandomized controlled trialNeutrophil-tolymphocyte ratiolawMedicineNeutrophil-to-lymphocyte ratioLiver NeoplasmsGastroenterologyMicroRNAGeneral MedicineSorafenibPrognosisTreatment OutcomeLiver030220 oncology & carcinogenesisHepatocellular carcinomaBiomarker (medicine)030211 gastroenterology & hepatologyAdverse events; Angiopoietin; Biomarker; Hepatocellular carcinoma; MicroRNA; Neutrophil-tolymphocyte ratio; Polymorphisms; Sorafenib; Vascular endothelial growth factor; Gastroenterologymedicine.drugAdverse eventSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsSingle-nucleotide polymorphismAngiopoietin03 medical and health sciencesInternal medicineBiomarkers TumorHumansNeoplasm InvasivenessPolymorphismNeutrophil to lymphocyte ratioAdverse effectbusiness.industryBiomarkermedicine.diseasedigestive system diseasesClinical Trials Phase III as TopicDrug Resistance NeoplasmAdverse eventsEtiologyVascular endothelial growth factorbusinessPolymorphisms
researchProduct

Molecular target therapy for bone metastasis : starting a new era with denosumab, a RANKL inhibitor

2014

Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the …

OncologyMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaClinical BiochemistryAntineoplastic AgentsBone NeoplasmsAntibodies Monoclonal HumanizedZoledronic AcidMetastasisProstate cancerBreast cancerInternal medicineDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyBiologyPharmacologyDiphosphonatesbusiness.industrybone metastasis breast cancer denosumab prostate cancer skeletal-related events solid tumorsRANK LigandImidazolesBone metastasismedicine.diseaseSurgeryZoledronic acidDenosumabTreatment OutcomeMonoclonalPractice Guidelines as TopicHuman medicineDenosumabbusinessRANKL InhibitorEngineering sciences. Technologymedicine.drugExpert opinion on biological therapy
researchProduct